BioNTech to Host First Edition of Innovation Series on Diversified Pipeline, Latest Technology Innovations
21 June 2022 - 01:30AM
MAINZ, Germany, June 20, 2022 (GLOBE
NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or the
"Company”) will host the first edition of the Company’s Innovation
Series on Wednesday, June 29th, 2022. The virtual event will
provide an update on BioNTech’s clinical progress across its
pipeline and provide a deep-dive on scientific and technology
innovation from its proprietary research engine.
Investors and the interested public are invited
to join a webcast with investment analysts at 8:00 a.m. EDT (2:00
p.m. CEST). Online participation will be listen-only. To listen to
the webcast, you will first need to register at the following link.
You will then be able to access the slide presentation and audio of
the webcast via this link and log in using the same email address
you used to register. The platform will open ten minutes prior to
the start of the event.
A replay of the webcast will be available
shortly after the conclusion of the call and archived on the
Company’s website for 30 days following the call.
About BioNTechBiopharmaceutical
New Technologies is a next generation immunotherapy company
pioneering novel therapies for cancer and other serious diseases.
The Company exploits a wide array of computational discovery and
therapeutic drug platforms for the rapid development of novel
biopharmaceuticals. Its broad portfolio of oncology product
candidates includes individualized and off-the-shelf mRNA-based
therapies, innovative chimeric antigen receptor T cells,
bi-specific checkpoint immuno-modulators, targeted cancer
antibodies and small molecules. Based on its deep expertise in mRNA
vaccine development and in-house manufacturing capabilities,
BioNTech and its collaborators are developing multiple mRNA vaccine
candidates for a range of infectious diseases alongside its diverse
oncology pipeline. BioNTech has established a broad set of
relationships with multiple global pharmaceutical collaborators,
including Genmab, Sanofi, Genentech, a member of the Roche Group,
Regeneron, Genevant, Fosun Pharma and Pfizer. For more information,
please visit www.BioNTech.de.
CONTACTS
Investor Relations Sylke Maas, Ph.D. VP
Investor Relations & Strategy Tel: +49 (0)6131 9084 1074
E-mail: Investors@biontech.de
Media Relations Jasmina Alatovic VP Corporate
Communications E-mail: Media@biontech.de
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Feb 2024 to Mar 2024
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Mar 2023 to Mar 2024